Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127829001 | 12782900 | 1 | I | 20160823 | 20160927 | 20160927 | EXP | US-ROCHE-1833840 | ROCHE | 60.00 | YR | F | Y | 58.80000 | KG | 20160927 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127829001 | 12782900 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 1 | U | 125085 | |||||||||
| 127829001 | 12782900 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 2 | U | 125085 | 969 | MG | |||||||
| 127829001 | 12782900 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 3 | U | 125085 | |||||||||
| 127829001 | 12782900 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 4 | U | 125085 | |||||||||
| 127829001 | 12782900 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 5 | U | 125085 | |||||||||
| 127829001 | 12782900 | 6 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | CYCLE 1 | U | 0 | 52.8 | MG | |||||||
| 127829001 | 12782900 | 7 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | CYCLE 2 | U | 0 | 54.6 | MG | |||||||
| 127829001 | 12782900 | 8 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | CYCLE 3 | U | 0 | 54.6 | MG | |||||||
| 127829001 | 12782900 | 9 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | CYCLE 4 | U | 0 | 54.6 | MG | |||||||
| 127829001 | 12782900 | 10 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | CYCLE 5 | U | 0 | 54.6 | MG | |||||||
| 127829001 | 12782900 | 11 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127829001 | 12782900 | 1 | Papillary serous endometrial carcinoma |
| 127829001 | 12782900 | 6 | Papillary serous endometrial carcinoma |
| 127829001 | 12782900 | 11 | Papillary serous endometrial carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127829001 | 12782900 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127829001 | 12782900 | Anaemia | |
| 127829001 | 12782900 | Neutrophil count decreased | |
| 127829001 | 12782900 | Platelet count decreased | |
| 127829001 | 12782900 | Urinary anastomotic leak | |
| 127829001 | 12782900 | Vaginal fistula | |
| 127829001 | 12782900 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127829001 | 12782900 | 1 | 20101104 | 0 | ||
| 127829001 | 12782900 | 2 | 20101129 | 0 | ||
| 127829001 | 12782900 | 3 | 20110106 | 0 | ||
| 127829001 | 12782900 | 4 | 20110127 | 0 | ||
| 127829001 | 12782900 | 5 | 20110309 | 0 | ||
| 127829001 | 12782900 | 6 | 20101104 | 0 | ||
| 127829001 | 12782900 | 7 | 20101129 | 0 | ||
| 127829001 | 12782900 | 8 | 20110106 | 0 | ||
| 127829001 | 12782900 | 9 | 20110127 | 0 | ||
| 127829001 | 12782900 | 10 | 20110309 | 0 |